Aditxt, Inc. (“Aditxt”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, announces this past Friday, July 12th, Aditxt, its wholly owned subsidiary Adifem, Inc., and Evofem Biosciences, Inc.’s (“Evofem”) (OTCQB: EVFM) amended and restated their Merger Agreement. This amended and restated Merger Agreement, among others, addresses pre-closing issues critical for Evofem’s future success, including interim financing needs. The other revisions to the Merger Agreement, alongside additional interim financing for Evofem, include substituting cash for Aditxt’s common stock as the consideration for Evofem’s common stock in the merger and additional changes relating to it.
Read the full article: Aditxt and Evofem Amend and Restate Merger Agreement, Targeting September 30 Closing //
Source: https://www.businesswire.com/news/home/20240717745987/en/Aditxt-and-Evofem-Amend-and-Restate-Merger-Agreement-Targeting-September-30-Closing